Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment
- PMID: 31940494
- PMCID: PMC6963791
- DOI: 10.1016/j.celrep.2019.12.034
Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment
Abstract
Although there are many prospective targets in the tumor microenvironment (TME) of high-grade serous ovarian cancer (HGSOC), pre-clinical testing is challenging, especially as there is limited information on the murine TME. Here, we characterize the TME of six orthotopic, transplantable syngeneic murine HGSOC lines established from genetic models and compare these to patient biopsies. We identify significant correlations between the transcriptome, host cell infiltrates, matrisome, vasculature, and tissue modulus of mouse and human TMEs, with several stromal and malignant targets in common. However, each model shows distinct differences and potential vulnerabilities that enabled us to test predictions about response to chemotherapy and an anti-IL-6 antibody. Using machine learning, the transcriptional profiles of the mouse tumors that differed in chemotherapy response are able to classify chemotherapy-sensitive and -refractory patient tumors. These models provide useful pre-clinical tools and may help identify subgroups of HGSOC patients who are most likely to respond to specific therapies.
Keywords: matrisome; mouse model; ovarian cancer; serous; tumor microenvironment.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
O.J.S. is supported by AstraZeneca, Novartis, and Cancer Research Technology. R.D. serves on the scientific advisory board of Repare Therapeutics and Siamab Therapeutics. F.R.B. serves on the scientific advisory board of Verseau Therapeutics. The authors declare no other competing interests.
Figures








References
-
- Bailey P., Chang D.K., Nones K., Johns A.L., Patch A.M., Gingras M.C., Miller D.K., Christ A.N., Bruxner T.J., Quinn M.C., Australian Pancreatic Cancer Genome Initiative Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52. - PubMed
-
- Bergamini A., Ferrero S., Leone Roberti Maggiore U., Scala C., Pella F., Vellone V.G., Petrone M., Rabaiotti E., Cioffi R., Candiani M., Mangili G. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. Expert Opin. Investig. Drugs. 2016;25:1405–1412. - PubMed
Publication types
MeSH terms
Grants and funding
- 27947/CRUK_/Cancer Research UK/United Kingdom
- A16354/CRUK_/Cancer Research UK/United Kingdom
- A17196/CRUK_/Cancer Research UK/United Kingdom
- P50 CA228991/CA/NCI NIH HHS/United States
- A27947/CRUK_/Cancer Research UK/United Kingdom
- A16354 /CRUK_/Cancer Research UK/United Kingdom
- 20118/Z/16/Z /WT_/Wellcome Trust/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- BIDS3000032485/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- HHSN261200800001E/CA/NCI NIH HHS/United States
- 21139/CRUK_/Cancer Research UK/United Kingdom
- A25714/CRUK_/Cancer Research UK/United Kingdom
- HHSN261200800001C/RC/CCR NIH HHS/United States
- 25714/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
Research Materials